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The effect of body condition on the distribution and composition of 16 
perfluoroalkylated substances (PFASs) in liver, blood, kidney, adipose tissue and muscle of 
Arctic fox (Vulpes lagopus) from Svalbard was investigated. Quantifiable concentrations of 
the PFASs were found in all samples (n=18). Overall, PFASs concentrations were highest in 
liver, followed by blood and kidney, while lowest concentrations were found in adipose tissue 
and muscle. Lean foxes had higher concentrations of ∑PFASs and several individual 
compounds in adipose tissue. Higher concentrations of perfluorodecanoic acid and 
perfluoroheptane sulfonic acid in liver, kidney and blood were found in lean foxes, and 
perfluorononanoic acid concentrations in liver and blood increased with decreasing body 
condition. The lowest ratio between perfluorooctane sulfonamide and its metabolite 
perfluorooctane sulfonic acid (PFOS) was in liver, muscle and kidney while significantly 
higher proportions were found in adipose tissue and blood. Kidney was the organ containing 
most branched PFOS (32 % of sum linear and branched PFOS), while the remaining tissues 
had ~20 % of branched PFOS. Arctic mammals have large variability in fat content, and 
increased concentration of PFASs in target organs of individuals with poor body condition 
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Perfluoroalkylated substances (PFASs) are synthetic chemicals used since the 1950’s 
for commercial and industrial purposes. In 2009, perfluorooctane sulfonic acid (PFOS), its 
salts and perfluorooctane sulfonyl fluoride were defined as persistent organic pollutants 
(POPs) in the Stockholm convention (listed in Part III of Annex B of the Convention). This 
was due to their persistence in the environment, ability for long-range transport, 
bioaccumulative character and toxic potential. Nevertheless, the production and use of PFOS 
and related compounds is only heavily restricted and not completely banned like many other 
POPs. So far PFOS, its salts and perfluorooctane sulfonyl fluoride are the only PFASs defined 
as a POP, though other PFASs have the same persistent and toxic qualities 
1
.  
As a result of substantial persistence in the environment and long-range transportation, 
PFASs are now found in the Arctic 
2
. Moreover, modeled ocean water concentrations in the 
Arctic showed that PFASs concentration are expected to increase until 2030, even if 
emissions are substantially reduced or eliminated in near future 
3
. Certain PFASs, such as 
PFOS, have similar biomagnifying capacity as the well-known legacy POPs such as, 
polychlorinated biphenyls (PCBs), dichlorodiphenyltrichloroethane (DDTs) and 
polybrominated diphenyl ethers  (PDBEs) 
4
. In fact, PFOS has been reported at higher 
concentrations than legacy POPs (PCBs, DDTs and PDBEs) in polar bears  
(Ursus maritimus) 
5
 and Arctic foxes (Vulpes lagopus) 
6
. These high concentrations of PFASs 
in Arctic top predators are of great concern due to increased possibility of health issues. 
Arctic mammals, especially the Arctic fox, have large seasonal variability of fat 
content and rely heavily on regulation of lipid metabolism 
7
. They are therefore sensitive to 
the effects of POPs due to release and redistribution of POPs stored in adipose tissue 
8
. 
Wildlife reports have mainly focused on PFASs in liver and blood due to high accumulation 
in the enterohepatic system 
9
. Reports on tissue distribution of PFASs in mammals are 
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, polar bears 
13
 and mice 
14
. These previous studies show species-
specificity in tissue distribution
15
. Nevertheless, only one of these studies has examined tissue 
distribution of PFASs on Arctic mammals 
13
. Knowledge of tissue distribution in different 
species is crucial in order to map all potential harmful effects PFASs can give. 
Chronic exposure to PFASs are correlated with potential health effects, such as 
metabolic disruption 
16
 , developmental toxicity 
17
, thyroid disruption 
18
, and liver-and 
pancreas carcinogenicity 
19
, in both animals and humans. Metabolic disruption and liver-and 
pancreas carcinogenicity are associated with PFASs’ ability to mediate the peroxisome 
proliferator-activated receptor (PPAR) pathway 
16, 19
. PPARs, are found in three isoforms 
which all take part in regulating target genes involved in fatty acid metabolism, in addition to 
moderate the effect of peroxisome proliferators 
20
. PPARs are activated by  fatty acids, as well 
as PFAS, which are structurally similar to fatty acids, having a strong hydrophobic body and 
polar head group 
21
. Previous in vitro and epidemiological studies suggest that PFASs 
exposure is associated with metabolic disruption, obesity and diabetes 
22, 23
. Uncertainties 
evolve around if variation of body condition further affects concentration of PFASs in tissues 
and may amplify the effects of PFASs.  
The aim for this study is to examine concentrations and patterns of PFASs within and 
between tissues of the Arctic fox and the effect body condition have on it. The large 
fluctuations in adipose tissue of Arctic foxes indicate that this species is a good reference 
model to look at the implications how body condition affects distribution of contaminants. As 
far as I know this is the first study reporting the effect of body condition on distribution and 




Methods and materials 
Sample collection 





E). Baited traps were used to collect the foxes during the annual harvest 
between 1
st
 of November and 15
th
 of March in 2010/2011 (n=13) and 2011/2012 (n=5). All 
foxes were weighted, sex-determined, and skinned before shipped frozen to Tromsø for the 
final dissection. 
Samples of liver, kidney, abdominal adipose tissue and muscle were wrapped in 
aluminum foil and stored at -20
o
C until further use. Samples of whole blood were taken from 
the heart and stored with the other tissues. Individual body condition was also assessed during 
the dissection, and was defined as either lean or fat. The age of the Arctic foxes was 
determined by counting the annuli in the cementum of a sectioned canine tooth 
24
. All foxes 
used in this study were between one and three years old. The females (n=7)  were not 
expected to have given birth since Svalbard vixens do not reach maximum pregnancy rates 
before the age of four 
25
. Also, there were no marks from reproduction on the uterus of the 
vixens used in this study.   
PFASs analyses 
The PFASs analysis was conducted at the Norwegian Institute for Air Research 
(NILU). All solvents used in this experiment were of Lichrosolv® grade and were purchased 
from Merck-Schuchardt (Hohenbrunn, Germany). The method used for preparing the samples 
for analysis has previously been described by Powley, et al. 
26
. In short, all samples (1 g) were 
added 0.1 ng/µl isotopically-labeled internal standards, which were used to calculate PFASs 
concentrations. Isotopically-labeled compounds used as internal standard were of >98% 
















C2PFUnDA) and MPFDoDA (
13
C2PFDoDA).  
Acetonitrile was blended in with the samples followed by ultrasonic bath and centrifuged for 
sedimentation (2000 rpm). The supernatant was concentrated to 1 ml using a RapidVap 
(Rapid Vap; Labconco corp., Kansas city, MO, USA). 25 mg ENVI-Carb 120/400 (Supelco, 
PN, USA) and glacial acetic acid was prepared and mixed with the supernatant. The mixture 
was centrifuged (10 000 rpm), and the supernatant solution was transferred to an auto injector 
vial where recovery standard (RSTD) was added. The RSTD, which were used to measure 
percentage recovery, contained 3,7-dimethyl-branched perfluorodecanoic acid (bPFDA). It 
was of 97 % purity and was obtained from ABCR (Karlsruhe, Germany). Prior to the 
ultrahigh pressure liquid chromatography triple-quadruple mass-spectrometry (UHPLC-
MS/MS) analysis the extract was added in a liquid chromatography-vial with 2 mM 
ammonium acetate in HLB-water (NH4OAc, ≥ 99%, Sigma-Aldrich, St. Louis, MO, USA) in 
a 50/50 mixture. PFASs were analyzed by UHPLC-MS/MS as previously described by 
Hanssen, et al. 
27
. The atomic mass of the sulfonate anions were taken into account for all the 
concentration calculations. 





To assess the possible confounding effect of diet on PFASs exposure, stable isotope 
ratios of nitrogen (δ
15
N) and carbon (δ
13
C) in muscle were analysed 
28
. Muscle SIA is 
expected to provide dietary information from the previous one to two months in the Arctic 
fox
28
.   
Approximately 1 g (cm
3
) of muscle tissue was dried for 2-3 days at 60°C before it was 
grounded into a fine powder in a bread-mill homogenizer (TissueLyzerll, Qiagen Gmbh, 
Hilden, Germany) and 0.4 mg (±0.05 mg) fine powder was put into a tin container. Stable 
isotope analysis was performed at the Stable Isotopes in Nature Laboratory (SINLAB), New 
Brunswick, Canada as previously described by Ehrich, et al. 
29
. In short, samples were 
6 
 
combusted in a Carlo Erba NC2500 Elemental Analyzer before delivery to a Finnigan 
MatDelta Pluss mass spectrometer (Thermo Finnigan, Bremen, Germany). Stable isotope 
signatures are expressed as parts per thousand (‰) relative to a standard as follows 












N, Peedee belemnite carbonate and atmospheric 




C reflects the lipid content of the tissue sample, the 
model based normalisation for muscular tissue was used to correct the value of δ
13
C for lipid 




Quality control was assessed according to Hansen et al 
27
. In order to reduce 
background interference, a blank was run with every 10 samples. The blank was treated 
identically to the other samples, except that no tissue was added. None of the blanks in this 
study had contamination. Recovery of the mass labeled internal standards ranged for liver 
between 45-125 %, for adipose tissue 35-125 % and for blood, kidney and muscle between 
50-115 %. A certified reference material was run with every 10 samples to assure quality of 
the analysis. This was used to minimize the fluctuations between samples made at different 
times. The control used for liver, kidney, muscle and adipose tissue, was pike IRMM-427, 
sample ID 0119. For the blood sample, a blood/serum control was used (SRM 1958, NIST, 
Gaithersburg, MD, USA).  
Data analysis 
Statistical analyses were carried out by using the statistical program R, version 3.0.2 
(R Core Team, 2013).  
Compounds detected in >60% of the samples in a given tissue were used for statistical 
analyses. Non-detected values of the compounds used in the analysis were set to be half the 
limit of detection (LOD). LOD is expressed as the concentration derived from the lowest 
7 
 
measure that can be detected with reasonable certainty for a given analytical procedure 
31
. The 
tissues with detected samples of less than 60 % were removed from the mixed models for the 
given compounds. Furthermore, the whole compound was removed from the ∑PFASs 
analyses, and for the analyses of the two subgroups, ∑perfluorocarboxylic acids (PFCAs) and 
∑perfluoroalkylated sulfonic acid (PFSAs).   
Linear mixed-effects models was applied using the R-library lme4 
32
, which were used 
to analyze the effect of explanatory variables on distribution of PFASs in Arctic fox tissues. 
The most parsimonious model for summed and individual PFASs was selected using ∑PFASs 
as a response variable. The possible explanatory variables included in the global model, 
applied as fixed effects were tissue (liver, blood, kidney, adipose tissue and muscle), body 




C, while individual was applied as a random effect. Age 
and gender were not included as explanatory variables since almost all the foxes were 
between 1-2 years old (two foxes were 3) and none of the females were expected to have 
reproduced. As our study is based on planned comparisons of tissue and body condition the 
interaction between them were kept in all models. From the pool of models we selected the 
most parsimonious model with the lowest value of Akaike’s Information Criterion corrected 
for small sample size (AICc)
33
. The most parsimonious model was further applied for 
individual PFASs, ∑PFASs, ∑PFCAs and ∑PFSAs, the ratios of PFOS:PFOSA and the ratio 
of branched and linear PFOS. One outlier was removed in the analysis of PFOS:PFOSA, 
however, removing this value did not change the estimates. PFOS used in the models for 
individual compounds, ∑PFASs and ∑PFSAs was based on the sum of branched and linear 
PFOS. 
The MCMCglmm (MCMCglmm, Marcov chain Monte Carlo Sampler simulations for 
Bayesian estimations of Generalized Linear Mixed Models) package 
34
 were used to calculate 
8 
 
the 95 % confidence intervals of the effect. 500 000 MCMC iterations were used, retaining 
every fifth values in the chain. 
Assumptions of constant variance and approximate normal distribution of residuals 
were determined through plots of residuals against fitted values and normal-and quantile-
quantile plots 
35
. To meet the assumptions, all PFASs concentrations were log-transformed 
prior to the analyses. Additionally, a constant (0.05) was added to take the few non-detected 
compounds into account and the constant was chosen when residuals were approximately 









Results and discussion 
Model selection 
The result from the model selection showed that the most parsimonious model 
explaining the variation of ΣPFASs contained δ
15
N, tissue and body condition as fixed factors 
and individual as random variable (see Supporting Information).  
The relationship between body condition and tissue showed great evidence to explain 
the variation of PFASs, while variation was weakly explained by δ
15
N, respectively.  
Tissue concentrations of PFASs 
PFOS was the dominating PFASs in all Arctic fox tissues, while perfluorononanoic 
acid (PFNA) was the most dominating PFCAs followed by perfluoroundecanoic acid 
(PFUnA) and perfluorotridecanoic acid (PFTrA) (Table 1). PFTrA was observed at similar 
concentrations as PFUnA in all tissues except adipose tissue where PFTrA was detected in 
less than 60 % of samples. These findings are consistent with previous studies on Arctic 
predators, where PFOS is the dominating PFASs, while in the PFCAs group, PFNA, PFUnA 
and PFTrA are found to have among the highest concentrations 
6, 13, 36
. Perfluorohexane 
sulfonic acid (PFHxS) and perfluorooctanoic acid (PFOA) were detected in all tissues 
although at lower concentrations than PFOS, PFNA and PFUnA (Figure 1, Table 1). 
Perfluorodecanoic acid (PFDcA), perfluorododecanoic acid (PFDoA), perfluorotetradecanoic 
acid (PFTeA), PFOSA and perfluoroheptane sulfonic acid (PFHpS) were detected in most 
samples, though not detected over 60 % of samples in adipose tissue, and additionally PFTeA 




Table 1. Geometric mean concentrations (ng/g wet weight), standard error (SE) for all 
detected compounds* and range for all PFASs in tissues of the Arctic fox from Svalbard.  
 








2.7  ± 0.49 
(0.81 - 7.45) 
1.35 ± 0.24 
0.47 - 3.5) 
0.23 ± 0.05 
(0.01 - 0.64) 
0.10 ± 0.06 
(0.01 - 0.88) 
0.26 ± 0.01 




14 ± 3.2 
(3.95 - 55) 
3.8 ± 0.7 
(1.4 - 13) 
1.9 ± 0.62 
(0.53 - 9.8) 
0.33 ± 0.26 
(0.09 - 4.4) 
0.41 ± 0.55 




4.15 ± 0.79 
(1.2 - 12.5) 
0.82 ± 0.13 
(0.32 – 2) 
0.46 ± 0.11 
(0.15 - 1.9) 
n.d 
(0.01 - 0.65) 
0.13 ± 0.02 




5.2 ± 1.5 
(1.2 - 26) 
1.3 ± 0.37 
(0.34 - 6.4) 
0.79 ±  0.28 
(0.26 - 4.9) 
0.09 ± 0.08 
(0.004 - 1.1) 
0.25 ± 0.06 




0.72 ± 0.21 
(0.21 - 4.05) 
0.175 ± 0.06 
(0.05 - 1.15) 
0.1 ± 0.06 
(0.003 - 1.0) 
n.d. 
(0.004 - 0.23) 
0.04 ± 0.015 




6.0 ± 1.79 
(1.55 - 33) 
1.4 ± 0.63 
(0.30 - 12) 
0.42 ± 0.21 
(0.14 - 4.1) 
n.d. 
(0.01 - 1.3) 
0.18 ± 0.06 




2.3 ± 0.62 
(0.45 - 10) 
n.d. 
(47 - 47) 
0.1 ± 0.02 
(0.03 - 0.49) 
n.d 
(0.034 - 0.71) 
0.04 ± 0.01 





(0.21 - 55) 
0.69  ± 0.25 
(0.05 – 13) 
0.3 ± 0.11 
(0.003 - 9.8) 
0.065 ± 0.04 
(0.004 - 4.4) 
0.07 ± 0.02 
(0.002 – 1.2) 




0.38 ± 0.53 
(0.01 - 9.8) 
0.84 ± 1.5 
(0.08 – 28.5) 
0.1 ± 0.16 
(0.005 - 2.8) 
n.d. 
(0.034 - 1.5) 
n.d. 
(0.001 – 0.44) 




5.2 ± 2.2 
(0.75 – 36) 
4.6 ± 2.2 
(0.54 - 29) 
3.0 ± 1.6 
(0.27 - 27) 
0.47 ± 0.24 
(0.04 - 3.9) 
0.745 ± 0.34 




1.3 ± 0.3 
(0.12 - 5.45) 
0.305 ± 0.08 
(0.05 - 1.4) 
0.23 ± 0.05 
(0.005 - 0.68) 
n.d. 
(0.02 - 0.155) 
0.02 ± 0.01 




80 ± 15 
(9.7 – 275) 
10 ± 2.1 
(1.1 - 29) 
8.6 ± 2.1 
(0.74 - 35) 
0.79 ± 0.46 
(0.09 - 7.8) 
2.0 ± 0.36 




8.1 ± 8.2 
(0.12  - 275) 
2.4 ± 1.2 
(0.05 - 29) 
1.9 ± 1.07 
(0.005 - 35) 
0.2 ± 0.19 
(0.02 - 7.8) 
0.30 ± 0.22 




3.7 ± 2.50 
(0.01 – 275) 
0.97 ± 0.42 
(0.05 - 29) 
0.49 ± 0.34 
(0.003 - 35) 
0.09 ± 0.06 
(0.004 - 7.8) 
0.11 ± 0.07 
(0.002 - 5.5) 
*All compounds found above the detection limit in at least 60 % of the samples for a given tissue. 
n.d.= not detected 
12 
 
Odd-numbered PFCAs were found in greater amount than the even-numbered in all 
tissues, and concentrations of odd-numbered PFCAs decreased with increasing chain length 
(Table 1). These trends are in agreement with previous findings on Arctic foxes, polar bears 
and seabirds 
6, 13, 37, 38
. Perfluorobutane sulfonic acid (PFBS), Perfluorodecane sulfonic acid 
(PFDcS), perfluorohexanoic acid (PFHxA) and perfluoroheptanoic acid (PFHpA) were not 
detected in any of the tissue samples of Arctic foxes, which is consistent with previous 
literature 
39
. PFBS, PFHxA and PFHpA are neither considered bioaccumulative nor 
biomagnifying, and are usually not detected in wildlife samples 
39
. PFDcS has been detected 
in sea birds  
37, 40, 41
 and polar bears 
13
, though at low concentrations (e.g 1.8 ng/g ww in blood 
of polar bears). Polar bears, have in general five to ten times higher concentrations of PFASs 
than Arctic foxes 
6
, which may explain why PFDcS were detected in polar bears but not 
Arctic foxes.  
The concentrations of PFASs differed between Arctic fox tissues (Table 1). The 
highest concentrations of PFASs were found in the liver, followed by blood and kidney. The 
lowest concentrations were found in adipose tissue and muscle. These findings are in 
accordance with previous literature on mammalian predators 
11, 13, 42
. It is well established that 
PFASs go through extensive uptake from enterohepatic circulation, and accumulate mostly in 
the liver 
1
. Furthermore, the distribution of PFASs is affected by localized proteins 
43, 44
. In 
detail, PFASs have great affinity to liver fatty acid-binding protein (L-FABP), which partly 
explains their high concentration in the liver 
1, 21, 43, 45
. Additionally, recent modeled studies 
suggest that PFASs have great affinity towards phospholipids 
44, 46
. These are found in large 
quantities in the liver, and may contribute to the high concentrations of PFASs in this  
organ 
44, 46
. Blood had the second highest concentration of PFASs. This is due to their affinity 
to albumin 
43, 44, 47-49
. Reabsorption of PFASs from the gut and urine by passive diffusion and 
organic anion transporters (OATs) into the blood probably plays a significant role in high 
13 
 
concentrations and the long half-life of PFASs in blood
50
. Phospholipids, L-FABPs and OATs 
are found in the kidney, which may explain the high concentration of PFASs in this organ 
44
. 
Furthermore, the high concentrations of PFASs in the kidney may also indicate excretion of 
these compounds through urine 
51




PFASs composition was similar between Arctic fox tissues (Figure 1a, 1b). These 
findings are in agreement with studies on harbor seals, where the same composition was  
seen 
10
. However, these results are not in agreement with the PFASs composition in polar 
bears, in which longer-chained PFCAs are found in adipose tissue while shorter-chained 
PFCAs are found in liver and blood 
13
.  
Effect of body condition  
Concentrations of summed and individual PFASs differed between lean and fat foxes 
(Figure 2). For ∑PFASs, adipose tissue was the only body compartment affected by body 
condition, where the lean foxes had four times [95% Cl: 2.0, 10] higher concentrations of 
∑PFASs than the fat foxes. The same trend was seen for ∑PFSAs, where lean foxes had 
seven times [95% Cl: 2.6, 19] higher concentration of ∑PFSAs in adipose tissue than fat 
foxes. This similar trend in ∑PFASs and ∑PFSAs is explained by the large concentration and 
contribution of PFSAs in ∑PFASs. The trend for ∑PFCAs was different, as lean foxes had 
over two times [95% Cl: 1.1, 4.4] higher concentrations of ∑PFCAs in liver, blood and 
kidney. Adipose tissue of lean individuals had fivefold [95% Cl: 2.4, 9.4] higher 
concentrations of ∑PFCAs than fat foxes. Muscle were not significantly affected by body 
condition, as lean individuals only had 0.3 times [95% Cl: -0.6, 2.6] higher concentrations of 





Figure 1. Percent composition of PFASs (a) and PFCAs (B) within each tissue in lean and fat 
Arctic foxes from Svalbard (n=18). The values are based on arithmetic mean. 
 
Analysis on individual compounds showed that medium chain length PFCAs (C9-C11) 
and short chain length PFSAs (C6-C7) were the compounds affected by decreased body 
condition. Lean foxes had twice as high [95% Cl: 1.2, 4.5] concentrations of PFNA in liver, 
blood and adipose tissue compared to fat foxes. Concentrations of PFDcA were two times 
[95% Cl: 1.2, 3.7] higher in liver, kidney and blood of lean individuals compared to the fat 
foxes. Eight times [95% Cl: 3.4, 20] higher concentration of PFUnA was found in adipose 
tissue of the lean foxes compared to the fat individuals. For PFHxS, adipose tissue was the 
only tissue affected by body condition, with lean foxes having three times [95% Cl: 1.0, 10] 
higher concentration of PFHxS than fat foxes. Liver, kidney and blood of lean foxes had two 





Figure 2.  Concentrations (ng/g wet weight) of individual and sum (Σ) PFSAs, PFCAs and 
PFASs, in liver (Li), blood (Bl), kidney (Ki), adipose tissue (Ad) and muscle (Mu) of lean 
(dark grey)  and fat (white) Arctic foxes form Svalbard (n=18). Y-axis is on a logarithmic 
scale.  
 
Concentrations of PFOSA, PFOS, PFOA, PFDoA, PFTrA and PFTeA were not 
affected by body condition in any tissue analyzed in our study. Similarly, studies on sea otter 
(Enhydra lutris nereis) and harbor seals showed that PFOS and PFOA measured in liver were 
not affected by body condition 
52, 53
. This is further supported in a study on male mink 

































































































































































PFDoA, PFTrA in the liver was not affected by body condition 
54
.  However, in the same 
study PFNA and PFDcA were also found not to differ between body condition in the liver, 
while in this study these compounds were found at higher concentration in that organ of lean 
foxes.   
The results from this study clearly show that adipose tissue concentrations of most 
PFASs vary with nutritional status. This may be explained by a concentration effect of the 
compound within the adipose tissue i.e. the reduction of adipose tissue in lean foxes lead to 
PFASs being stored in a smaller total lipid mass. A possible explanation for the increased 
concentrations in kidney, liver and blood may be explained by the lowered intake of food 
during fasting 
55
. Fasting leads to reduced resting metabolic rate 
55
 and reduced excretion of 
contaminants, which by its turn gives increased half-life and increased accumulation of 
contaminants 
56
. This may further, explain why medium chain length PFCAs are more 
affected by decreased body condition than the short chain length PFCAs. The short chain 
length PFCAs are water-soluble 
57
 and are highly eliminated through urine 
58, 59
. Medium 
chain length PFCAs, which are more hydrophobic, favor biliary enterohepatic 
 recirculation 
58, 59
. This means that reduced excretion and food intake will affect medium 
chain length PFCAs, more than short chain length PFCAs. Other mechanism may explain 
why shorter chained length PFSAs are affected by body condition while PFOS is not. 
PFOSA and PFOS concentration  
The estimated ratio between PFOSA and its metabolite PFOS were 0.0037 [CI: 0.001, 0.013] 
in liver, muscle and kidney, while significantly higher ratios were found in adipose tissue and 
blood, 0.042 [CI: 0.004; 0.40] and 0.068 [CI: 0.007, 0.66], respectively. Body condition had 
no effect on the ratio between PFOSA and PFOS (Figure 3a). The low PFOSA:PFOS ratio in 




Figure 3. Percent compositions of PFOSA and PFOS (a) and composition between linear and 
branched PFOS (b) within each tissue in lean and fat Arctic foxes from Svalbard (n= 18). The 
values are based on arithmetic mean. 
 
N-ethyl perfluorooctanesulfonamido ethanol (N-EtFOSA) via PFOSA to PFOS 
60
. This 
process is mainly catalyzed by cytochrome P450 enzymes (CYP2C9 and CYP2C19 in 
humans), which is expressed in liver 
61
. The higher proportion of PFOSA in blood and 
adipose tissue may be due to the absence or low activity of CYP enzymes in these body 
compartments resulting in slower degradation of PFOSA to PFOS. 
Branched and Linear PFOS concentration 
Kidney was the organ containing most branched PFOS (32 %), while the remaining 
tissues contained ~20 % of branched PFOS. Nevertheless, the branched and linear PFOS 
composition did not differ significantly between tissues (Figure 3b). Body condition did not 
have an effect on the proportion either. Branched PFOS were found in much higher 
proportion in Arctic foxes compared to polar bears, where branched PFOS varied between 
 ~0 % to 25 % depending on tissue 
62
. Moreover, the composition of branched and linear 
PFOS varied between tissues in polar bears 
62
, whereas no difference between tissues was 
18 
 
observed in the Arctic foxes of the present study. Inter-species variation in metabolism of 





In this study there was found that decreased body condition (lean foxes) increases the 
concentrations of PFASs in adipose tissue in Arctic foxes. Additionally, higher concentrations 
of PFDcA and PFHpS in liver, kidney and blood, and higher PFNA concentrations in liver 
and blood where found to increase with decreasing body condition. In general, Arctic 
mammals have large seasonal variability in fat content 
7, 66-68
, which affects concentration of 
PFASs in tissues and may amplify the its effects. The effects are not only related to the 
increased concentration of PFASs, but are also related to increased concentration of other 
POPs in target organs during decreased body condition which may further increase toxicity 
8
.  
Essentially, PFASs interfere with the PPAR-pathway by binding to the PPAR, and by binding 
to liver-FABPs which is directly involved in the transportation of fatty acids to the PPAR 
69
. 
Interference with the PPAR-pathway is related to metabolic disruption 
70, 71
. Future studies 
should focus on toxicity in animals in relation to body condition in order to map if decreased 
body condition amplify the possible effects of PFASs. The results also suggest that these large 
annual changes in body condition must be taken into account when performing time-trend 
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Table S1. Result of model selection based on log-transformed ∑PFASs as response variable. 





C, were applied as fixed effects, while individual was applied as a random effect. BC = 
Body condition, Df = Degrees of freedom, logLIK = logarithmic likelihoods of the fitted 
model, AICc = Akaike’s Information Criterion corrected for small sample size. 
Model Intercept Df logLik AICc Delta Weight 
BC+ Tissue + δ
15
N 3.07400 8 -101.969 221.7 0.0 0.473 




N 6.37700 9 -101.401 223.1 1.33 0.243 
BC + Tissue 1.21200 7 -104.847 225.1 3.34 0.089 
BC * Tissue + δ
15
N  3.49600 12 -98.678 225.4 3.69 0.075 
BC + Tissue + δ
13
C -0.41030 8 -103.974 225.7 4.01 0.064 




N  6.79900 13 -98.066 226.9 5.20 0.035 
BC * Tissue 1.63400 11 -101.767 228.9 7.20 0.013 
BC * Tissue + δ
15





N 9.39500 8 -109.842 237.5 15.74 0.00 
Tissue  + δ
15
N 2.45400 7 -111.995 239.4 17.64 0.00 
Tissue 0.80350 6 -113.854 240.7 19.00 0.00 
Tissue + δ
13
C 0.33750 7 -113.794 243.0 21.24 0.00 
BC 2.97200 3 -169.608 345.5 123.78 0.00 
BC + δ
15
N 4.83400 4 -168.942 346.4 124.64 0.00 
BC + δ
13
C 1.35000 4 -169.403 347.3 125.56 0.00 





N 8.13700 5 -168.814 348.3 126.63 0.00 
δ
15
N 4.21400 3 -171.409 349.1 127.38 0.00 
δ
13





N 11.16000 4 -170.844 350.2 128.44 0.00 
 
 
